This is a single-center, open-label and dose-escalation study to evaluate the safety, tolerability and dose-response relationship of HRS-9190 in healthy adults.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
53
Subject will receive the HRS-9190 injection at different dose levels.
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Adverse events (AEs)
Time frame: From the ICF signing date to Day 7.
The maximum observed concentration of HRS-9190 (Cmax)
Time frame: 0 hour to 1.5 hours after administration.
Time to Cmax of HRS-9190 (Tmax)
Time frame: 0 hour to 1.5 hours after administration.
Terminal elimination half-life of HRS-9190 (t1/2)
Time frame: 0 hour to 1.5 hours after administration.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.